BNR — Burning Rock Biotech Share Price
Last trade - 00:00- $61.02m
- -$7.64m
- CNY515.82m
- 69
- 59
- 46
- 60
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.77 | ||
| Price to Tang. Book | 0.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41% | ||
| Return on Equity | -37.03% | ||
| Operating Margin | -47.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 429.9 | 507.86 | 563.24 | 537.43 | 515.82 | 1,186.5 | n/a | 6.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
Directors
- Yansheng Han CHM (42)
- Leo Li CFO (36)
- Shaokun Chuai COO (41)
- Zhihong Zhang CTO (45)
- Hao Liu OTH (47)
- Feng Deng DRC (57)
- Gang Lu DRC
- Jing Rong DRC (39)
- Yunxia Yang DRC (47)
- Wendy Hayes IND (51)
- Min-jui Shen IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 10th, 2014
- Public Since
- June 12th, 2020
- No. of Employees
- 674
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 107,613,971
- Address
- No. 5 Xingdao Ring Road North, GUANGZHOU, 510005
- Web
- https://www.brbiotech.com/
- Phone
- +86 18501641666
- Auditors
- Ernst & Young Hua Ming LLP
Latest News for BNR
Upcoming Events for BNR
Burning Rock Biotech Ltd Annual Shareholders Meeting
Similar to BNR
Airsculpt Technologies
NASDAQ Global Market
Biodesix
NASDAQ Global Market
Exagen
NASDAQ Global Market
Fulgent Genetics
NASDAQ Global Market
InterCure
NASDAQ Global Market
FAQ
As of Today at 19:43 UTC, shares in Burning Rock Biotech are trading at $5.67. This share price information is delayed by 15 minutes.
Shares in Burning Rock Biotech last closed at $5.67 and the price had moved by -19.57% over the past 365 days. In terms of relative price strength the Burning Rock Biotech share price has underperformed the S&P500 Index by -31.07% over the past year.
The overall consensus recommendation for Burning Rock Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBurning Rock Biotech does not currently pay a dividend.
Burning Rock Biotech does not currently pay a dividend.
Burning Rock Biotech does not currently pay a dividend.
To buy shares in Burning Rock Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.67, shares in Burning Rock Biotech had a market capitalisation of $61.02m.
Here are the trading details for Burning Rock Biotech:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BNR
Based on an overall assessment of its quality, value and momentum Burning Rock Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Burning Rock Biotech is $3.97. That is 30.01% below the last closing price of $5.67.
Analysts covering Burning Rock Biotech currently have a consensus Earnings Per Share (EPS) forecast of -CNY6.94 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Burning Rock Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -18.43%.
As of the last closing price of $5.67, shares in Burning Rock Biotech were trading +20.89% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Burning Rock Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Burning Rock Biotech's management team is headed by:
- Yansheng Han - CHM
- Leo Li - CFO
- Shaokun Chuai - COO
- Zhihong Zhang - CTO
- Hao Liu - OTH
- Feng Deng - DRC
- Gang Lu - DRC
- Jing Rong - DRC
- Yunxia Yang - DRC
- Wendy Hayes - IND
- Min-jui Shen - IND